Vol 94, No 1 (2023)
Research paper
Published online: 2022-06-23

open access

Page views 3331
Article views/downloads 693
Get Citation

Connect on Social Media

Connect on Social Media

Expression pattern of circadian rhythm-related genes and its potential relationship with miRNAs activity in endometrial cancer

Ewelina Hermyt1, Nikola Zmarzly2, Celina Kruszniewska-Rajs3, Joanna Gola3, Agnieszka Jeda-Golonka1, Katarzyna Szczepanek1, Urszula Mazurek4, Andrzej Witek1
Pubmed: 36748323
Ginekol Pol 2023;94(1):33-40.


Objectives: The circadian clock is an autonomous oscillator that controls key aspects of cell physiology, including metabolism, transcriptional state, and cell signaling. Disturbances of circadian rhythms lead to disruption of cell and tissue homeostasis, which promotes carcinogenesis. The aim of the study was to determine the expression of circadian rhythm-related genes in endometrial cancer and to select miRNAs involved in the regulation of their expression. Material and methods: 50 endometrial tissue samples were collected from patients who underwent hysterectomy: 40 diagnosed with endometrial cancer and 10 without cancer. Expression profile of circadian rhythm-related genes was evaluated using microarrays and validated with RT-qPCR. MicroRNA expression was assessed using microarrays. Then mirTAR tool was used to identify miRNAs involved in the expression regulation of circadian rhythm-related genes. Results: CLOCK expression is disrupted in endometrial cancer, which may be due to miR-15b, miR-331-3p and miR-200a overexpression. Elevated NPAS2 and CSNK1D levels may be associated with miR-432 silencing. In addition, high miR-874 and miR-200a expression may be potentially responsible for the reduction of PER3 level. Conclusions: Change of CLOCK, CSNK1D, NPAS2 and PER3 expression may suggest that circadian rhythms are disrupted in endometrial cancer. A possible mechanism of the observed changes may be related to miRNAs activity.

Article available in PDF format

View PDF Download PDF file


  1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209–249.
  2. Wendeu-Foyet MG, Cénée S, Koudou Y, et al. Circadian genes and risk of prostate cancer: Findings from the EPICAP study. Int J Cancer. 2019; 145(7): 1745–1753.
  3. Masri S, Kinouchi K, Sassone-Corsi P. Circadian clocks, epigenetics, and cancer. Curr Opin Oncol. 2015; 27(1): 50–56.
  4. Bar I, Merhi A, Larbanoix L, et al. Silencing of casein kinase 1 delta reduces migration and metastasis of triple negative breast cancer cells. Oncotarget. 2018; 9(56): 30821–30836.
  5. Xu H, Wang Z, Mo G, et al. Association between circadian gene and cisplatin resistance in ovarian cancer cells: A preliminary study. Oncol Lett. 2018; 15(6): 8945–8950.
  6. Hadadi E, Taylor W, Li XM, et al. Chronic circadian disruption modulates breast cancer stemness and immune microenvironment to drive metastasis in mice. Nat Commun. 2020; 11(1): 3193.
  7. Markt SC, Valdimarsdottir UA, Shui IM, et al. Circadian clock genes and risk of fatal prostate cancer. Cancer Causes Control. 2015; 26(1): 25–33.
  8. Gao Q, Zhou L, Yang SY, et al. A novel role of microRNA 17-5p in the modulation of circadian rhythm. Sci Rep. 2016; 6: 30070.
  9. Szymczyk A, Macheta A, Podhorecka M. Abnormal microRNA expression in the course of hematological malignancies. Cancer Manag Res. 2018; 10: 4267–4277.
  10. Reinke H, Asher G. Crosstalk between metabolism and circadian clocks. Nat Rev Mol Cell Biol. 2019; 20(4): 227–241.
  11. Hermyt E, Zmarzły N, Grabarek B, et al. Interplay between miRNAs and genes associated with cell proliferation in endometrial cancer. Int J Mol Sci. 2019; 20(23).
  12. Lamia KA. Ticking time bombs: connections between circadian clocks and cancer. F1000Res. 2017; 6: 1910.
  13. Li HX. The role of circadian clock genes in tumors. Onco Targets Ther. 2019; 12: 3645–3660.
  14. Mocellin S, Tropea S, Benna C, et al. Circadian pathway genetic variation and cancer risk: evidence from genome-wide association studies. BMC Med. 2018; 16(1): 20.
  15. Ye Y, Xiang Yu, Ozguc FM, et al. The genomic landscape and pharmacogenomic interactions of clock genes in cancer chronotherapy. Cell Syst. 2018; 6(3): 314–328.e2.
  16. Gao LW, Wang GL. Comprehensive bioinformatics analysis identifies several potential diagnostic markers and potential roles of cyclin family members in lung adenocarcinoma. Onco Targets Ther. 2018; 11: 7407–7415.
  17. Zheng YQ, Bai YF, Yang S, et al. MircoRNA-629 promotes proliferation, invasion and migration of nasopharyngeal carcinoma through targeting PDCD4. Eur Rev Med Pharmacol Sci. 2019; 23(1): 207–216.
  18. Li B, Meng YQ, Li Z, et al. MiR-629-3p-induced downregulation of SFTPC promotes cell proliferation and predicts poor survival in lung adenocarcinoma. Artif Cells Nanomed Biotechnol. 2019; 47(1): 3286–3296.
  19. Wang S, Gao B, Yang H, et al. MicroRNA-432 is downregulated in cervical cancer and directly targets FN1 to inhibit cell proliferation and invasion. Oncol Lett. 2019; 18(2): 1475–1482.
  20. Yi C, Mu L, de la Longrais IA, et al. The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer. Breast Cancer Res Treat. 2010; 120(3): 663–669.
  21. Xue X, Liu F, Han Ye, et al. Silencing NPAS2 promotes cell growth and invasion in DLD-1 cells and correlated with poor prognosis of colorectal cancer. Biochem Biophys Res Commun. 2014; 450(2): 1058–1062.
  22. Lesicka M, Jabłońska E, Wieczorek E, et al. Altered circadian genes expression in breast cancer tissue according to the clinical characteristics. PLoS One. 2018; 13(6): e0199622.
  23. Cadenas C, van de Sandt L, Edlund K, et al. Loss of circadian clock gene expression is associated with tumor progression in breast cancer. Cell Cycle. 2014; 13(20): 3282–3291.
  24. Zhang Y, Huang F, Wang J, et al. MiR-15b mediates liver cancer cells proliferation through targeting BCL-2. Int J Clin Exp Pathol. 2015; 8(12): 15677–15683.
  25. Chava S, Reynolds CP, Pathania AS, et al. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma. Mol Oncol. 2020; 14(1): 180–196.
  26. Dong Y, Zhang N, Zhao S, et al. miR-221-3p and miR-15b-5p promote cell proliferation and invasion by targeting Axin2 in liver cancer. Oncol Lett. 2019; 18(6): 6491–6500.
  27. Wu B, Liu G, Jin Y, et al. miR-15b-5p promotes growth and metastasis in breast cancer by targeting HPSE2. Front Oncol. 2020; 10: 108.
  28. Chen R, Sheng Lu, Zhang HJ, et al. miR-15b-5p facilitates the tumorigenicity by targeting RECK and predicts tumour recurrence in prostate cancer. J Cell Mol Med. 2018; 22(3): 1855–1863.
  29. Wang H, Zhan Yu, Jin J, et al. MicroRNA-15b promotes proliferation and invasion of non‑small cell lung carcinoma cells by directly targeting TIMP2. Oncol Rep. 2017; 37(6): 3305–3312.
  30. Zhao C, Li Y, Chen G, et al. Overexpression of miR-15b-5p promotes gastric cancer metastasis by regulating PAQR3. Oncol Rep. 2017; 38(1): 352–358.
  31. Zhang H, Wang R, Wang M. miR-331-3p suppresses cell invasion and migration in colorectal carcinoma by directly targeting NRP2. Oncol Lett. 2019; 18(6): 6501–6508.
  32. Tian QQ, Xia J, Zhang X, et al. miR-331-3p inhibits tumor cell proliferation, metastasis, invasion by targeting MLLT10 in non-small cell lung cancer. Cancer Manag Res. 2020; 12: 5749–5758.
  33. Buranjiang G, Kuerban R, Abuduwanke A, et al. MicroRNA-331-3p inhibits proliferation and metastasis of ovarian cancer by targeting RCC2. Arch Med Sci. 2019; 15(6): 1520–1529.
  34. Suo HB, Zhang KC, Zhao J. MiR-200a promotes cell invasion and migration of ovarian carcinoma by targeting PTEN. Eur Rev Med Pharmacol Sci. 2018; 22(13): 4080–4089.
  35. Delangle R, De Foucher T, Larsen AK, et al. The use of microRNAs in the management of endometrial cancer: a meta-analysis. Cancers (Basel). 2019; 11(6).
  36. Eng GW, Virshup DM. Site-specific phosphorylation of casein kinase 1 δ (CK1δ) regulates its activity towards the circadian regulator PER2. PLoS One. 2017; 12(5): e0177834.
  37. Xu P, Ianes C, Gärtner F, et al. Structure, regulation, and (patho-)physiological functions of the stress-induced protein kinase CK1 delta (CSNK1D). Gene. 2019; 715: 144005.
  38. Rosenberg LH, Lafitte M, Quereda V, et al. Therapeutic targeting of casein kinase 1δ in breast cancer. Sci Transl Med. 2015; 7(318): 318ra202.
  39. Mazzoldi EL, Pastò A, Ceppelli E, et al. Casein kinase 1 delta regulates cell proliferation, response to chemotherapy and migration in human ovarian cancer cells. Front Oncol. 2019; 9: 1211.
  40. Yang ZG, Ma XD, He ZH, et al. miR-483-5p promotes prostate cancer cell proliferation and invasion by targeting RBM5. Int Braz J Urol. 2017; 43(6): 1060–1067.
  41. Zhou W, Yang W, Ma J, et al. Role of miR-483 in digestive tract cancers: from basic research to clinical value. J Cancer. 2018; 9(2): 407–414.
  42. Wang Li, Shi M, Hou S, et al. MiR-483-5p suppresses the proliferation of glioma cells via directly targeting ERK1. FEBS Lett. 2012; 586(9): 1312–1317.
  43. Tang W, Peng W, Zhang H, et al. Period 3, a tumor suppressor in non-small cell lung cancer, is silenced by hypermethylation. Int J Clin Exp Pathol. 2018; 11(1): 120–128.
  44. Hong Z, Feng Z, Sai Z, et al. PER3, a novel target of miR-103, plays a suppressive role in colorectal cancer in vitro. BMB Rep. 2014; 47(9): 500–505.
  45. Witek Ł, Janikowski T, Gabriel I, et al. Analysis of microRNA regulating cell cycle-related tumor suppressor genes in endometrial cancer patients. Hum Cell. 2021; 34(2): 564–569.
  46. Paszek S, Gabło N, Barnaś E, et al. Dysregulation of microRNAs in triple-negative breast cancer. Ginekol Pol. 2017; 88(10): 530–536.
  47. Niedźwiecki S, Piekarski J, Szymańska B, et al. Serum levels of circulating miRNA-21, miRNA-10b and miRNA-200c in triple-negative breast cancer patients. Ginekol Pol. 2018; 89(8): 415–420.
  48. Taoussi N, Alghamdi A, Futyma K, et al. Biological markers with potential clinical value in endometrial cancer - review of the literature. Ginekol Pol. 2017; 88(6): 331–336.